Synuclein aggregation in neuronal cells is the primary underlying cause of
synucleinopathies. Changes in gene expression patterns, structural modifications, and …

Dysregulation of innate and adaptive immunity can lead to alpha-synuclein (α-syn)
misfolding, aggregation, and post-translational modifications in Parkinson's disease (PD) …

Antibodies against phosphorylated alpha-synuclein (aSyn) at S129 have emerged as the
primary tools to investigate, monitor, and quantify aSyn pathology in the brain and peripheral …

Neuropathologically, Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are
characterized by the accumulation of insoluble aggregates of α-synuclein (α-syn) in the …

The abnormal aggregation and accumulation of alpha-synuclein (aSyn) in the brain is a
defining hallmark of synucleinopathies. Various aSyn conformations and post-translationally …

Parkinson's Disease (PD) is strongly linked to the aggregation of the protein α-synuclein (α-
syn), an intrinsically disordered protein. However, strategies to combat PD by targeting the …

Disorders of the central nervous system (CNS) represent a global health challenge and an
increased understanding of the CNS in both physiological and pathophysiological states is …

Genetic and neuropathological evidence strongly implicates aberrant forms of α-synuclein in
neurodegeneration. Antibodies specific for α-synuclein phosphorylated at serine 129 …

Abstract α-Synuclein (α-syn) accumulates as insoluble amyloid but also forms soluble α-syn
oligomers (αSOs), thought to be even more cytotoxic than fibrils. To detect and block the …

Aggregation of the protein α‐synuclein (α‐syn) into insoluble intracellular assemblies
termed Lewy bodies (LBs) is thought to be a critical pathogenic event in LB diseases such …